Study Supports Reason For Concern In Childhood And Adolescent Obesity

Study findings presented at the May 2008 Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting indicate that childhood and adolescent obesity negatively impacts vascular endothelial function, which relates to cardiac health.

Obesity has been increasing rapidly in the U.S. during the past 20 years and obesity in adults has been linked to cardiovascular disease. The incidence of obesity in children is also increasing and many cardiovascular diseases that are manifested in adulthood may actually begin in childhood. It is known that healthy endothelium (a single cell layer that lines all blood vessels) is key to maintaining vascular health. Endothelial “dysfunction” is a primary contributor to atherosclerotic cardiovascular disease (the buildup of fatty deposits on the inside walls of arteries) in adults and is associated with increased risk of heart attacks, stroke, and congestive heart failure. Endothelial function can be measured non-invasively in children using venous occlusion plethysmography (VOP), a technique that measures responses of arm blood vessel responses to an inflatable cuff that externally halts and restarts blood flow. This method has been shown to correlate with coronary artery function in adults with heart disease.

The study was designed to investigate the relationship between body mass index (BMI) and endothelial function measured via VOP in 76 children and adolescents ages nine through 18. BMI is a number calculated from a person’s weight and height and it provides a reliable indicator of the amount of body fat.

Judith Groner, MD, the presenting author of the study, a pediatrician in Ambulatory Pediatrics at Nationwide Children’s Hospital and a faculty member of The Ohio State University College of Medicine, said, “My colleagues in the Research Institute at Nationwide Children’s and I found that regardless of age, race or sex, obesity in children and adolescents negatively impacts their endothelial function. Considering the connection between endothelial function and heart disease, this information is alarming given the high prevalence of childhood and adolescent obesity in our country.”

Increased Risks For Infection And Dislocation Faced By Obese Patients Following Revision Hip Replacement Surgery

Along with age and injuries, obesity is a leading risk factor for osteoarthritis (OA), a painful and disabling joint disease. While excessive weight can aggravate the toll on almost any joint, obesity has been associated with a higher prevalence of hip OA and an increase in total hip arthroplasty (THA). Whether obese hip OA patients are more prone to postsurgical complications, however, remains open to debate and investigation, since the results of existing studies conflict. What’s more, only a few short-term studies have focused on how obesity affects the outcomes of revision THA. Compared to primary THA revision surgery is a longer and more complicated procedure implying more extensive tissue damage and a greater risk of prosthetic joint infections and dislocations, as well as other long-term complications.

Researchers at Geneva University Hospitals set out to evaluate the impact of obesity on the incidence of serious complications after revision THA, over a period of up to 5 years. The team also aimed to determine whether functional improvement, pain, and satisfaction 5 years after the second hip replacement differed between obese patients and patients of healthy weight. Their results, presented in the May 2008 issue of Arthritis Care & Research, reveal a strong correlation between obesity and high rates of adverse events, as well as lower functional gains and more persistent pain, after revision THA.

This long-term study focused on all patients who underwent a revision THA, excluding re-revisions, at the university’s hospital - the only public hospital serving the urban and suburban populations of Geneva, Switzerland - between 1966 and 2006. Of the 204 subjects, 114 were women and 90 were men, with a mean age of 71.6 years. Based on height and weight data obtained just before surgery, 52 patients, 25 percent of the sample, were defined as obese, with a body mass index (BMI) of 30 or more. The standard range for a normal BMI, the ideal weight to height ratio, is between 18 and 25. To further assess the association between BMI and postoperative outcomes, patients were also examined in 4 BMI categories: less than 25; 25 to 29.9, defined as overweight; 30 to 34.9; and 35 or more.

Based on patient records and follow-up examinations, the researchers first documented the occurrence of one or more adverse events within 5 years after the first revision THA: surgical site infection, dislocation of the prosthetic hip, or re-revision surgery for any cause. They then relied on trusted, hip-specific clinical evaluations, including the Harris Hip Score (HHS), along with in-person and phone interviews with patients, to measure each subject’s functional status, level of pain, and general satisfaction with the procedure 5 years later. Finally, researchers used statistical analyses, including incidence rates and hazard ratios, to compare the outcomes between obese and non-obese patients after revision THA.

Overall, 20 complications occurred in 17 (33 percent) of the 52 obese patients, compared with 18 events in 13 (9 percent) of the 152 non-obese patients. In terms of specific complications, the incident rate was 4 times higher for surgical site infection and 3.5 times higher for dislocation. Even more striking, the incidence rate for occurrence of one or more adverse events rose with rising BMI. This increase was small between normal and overweight patients - 1.5 times higher. Yet, it became significantly greater in the group with a BMI between 30 and 34.9 - 4.5 times higher than normal weight patients. And it escalated to an alarmingly increase in the group with a BMI of 35 or more - 10.9 times higher. In these calculations, adjustments were performed for age, sex, and preoperative health status.

For those patients scheduled for a 5 year follow-up visit, 83 percent of the obese patients and 85 percent of the non-obese patients were available for evaluation. In general, the obese patients had moderately lower functional improvements and higher levels of routine hip pain. However, patient satisfaction with the result of their revision THA was gauged to be about the same in both groups.

As its lead author, Dr. Anne Lübbeke, acknowledges, this study is limited by the relatively small number of adverse events resulting in large confidence intervals and restricting the adjustment for baseline differences between obese and non-obese patients to the most important confounding factors. Despite such weaknesses, the findings reinforce revision THA as a technically-challenging intervention, particularly when performed on obese patients.

“Surgeons, patients, and referring physicians should be aware of an increased risk in this patient group,” Dr. Lübbeke stresses. “Further studies are necessary to evaluate whether changes in medical preparation, surgical technique, and implant choice can help reduce the adverse event rate in obese patients undergoing revision THA.”

It’s a diet based on sensible eating and exercise. So what’s new?

Author Robert F. Kushner, MD, teaches medicine at Northwestern University and is director of the Wellness Institute at Northwestern Memorial Hospital. After seeing a lot of people who wanted — and needed — to lose weight, Kushner realized there’s no one-size-fits-all diet.

The Personality Type diet asks readers to answer 66 questions about their habits and attitudes toward eating, exercise, and coping. Based on the scores, a person falls into one or more “categories. For example, when it comes to eating, a person may be a “Mindless Muncher;” when it comes to exercise, an “All-or-Nothing Doer;” in coping, a “Can’t-Say-No Pleaser.”

In sections of the book appropriate for each type, Kushner offers specific advice helpful in changing the behaviors and attitudes with which a person self-identifies. This doesn’t mean other sections of the book aren’t full of useful advice. But because you’ve already identified things you need to change, Kushner’s method points you to the areas where diet and lifestyle change will do you the most good. Besides, most people will identify with more than one “type” in each category.

The Personality Type Diet: What You Can Eat
Kushner is big on “super foods.” These are all plant-based foods: Fruits, vegetables, grains, nuts, seeds, dried beans, lentils, and soy products. All are low- or moderate-fat foods rich in vitamins and other important nutrients.

The Personality Type diet isn’t a vegetarian diet, but there’s a definite focus on vegetarian dishes. Fish and poultry are on the menu. Lean red meat is OK, but not encouraged. You won’t find any beef dishes in the recipe section. There is, however, a stir-fry recipe using lean pork.

The Personality Type Diet: What the Experts Say
“At first glance, Dr. Kushner’s Personality Type Diet looks like one more over-hyped, hokey weight loss plan,” notes the July 2003 issue of the Tufts University Health & Nutrition Letter. “But the book actually explores practical methods that readers can use to restructure problematic eating and exercise habits tied to, well, their personalities.”

The Tufts reviewers say that the book is one of the more responsible weight-loss plans. They hail its “common sense” advise, “divided up into small, doable steps.”

The approach targets diet advice to people based on what they need the most help with and focuses strategies in three areas: eating, exercise, and coping with lots of realistic tips and tricks.

Tufts gives the book a five-out-of-five-stars “highly recommended” rating.

Kushner himself is a well-respected nutrition expert. However, neither he nor his co-author — wife Nancy Kushner, RN, MSN — is a clinical psychologist.

The Personality Type Diet: Food For Thought
Are you really interested in taking a look at your relationship with food — and changing it? If so, The Personality Type diet is an easy, fun, and useful place to start. But relationships, whether with food or loved ones, are hard to solve all by yourself. It may be helpful for you to consider exploring your food issues with a clinical psychologist.
 

Acomplia (Rimonabant), the new age weight loss medication is developed by French pharmaceutical giant Sanofi-Aventis, world’s third largest pharmaceutical company headquartered in Paris, France, to provide relief to the ever growing number of obese population across the world. Acomplia (Rimonabant), the eagerly awaited weight loss medication works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System). The EC System is believed to play a critical role in the regulation of food intake and energy expenditure of our body. Research findings indicate that these receptors are present on the surfaces of many cells throughout the body including fat cells and those in the hypothalamus - the brain region that is thought to determine our appetite. The chemical compounds produced by our body known as cannabinoids, latch on to the CB1 receptors, which are overactive in overweight and obese individuals, sending out a signal that prompts people to eat more and in the process makes them put on weight. But with the usage of diet pill Acomplia, we can halt the action of cannabinoid receptors and in the process will be capable of curbing our appetite. Studies conducted in the past have proved that genetically altered mice that lacked cannabinoid receptors ate less than their little mates even after 18 hours of fasting. It has also been observed that the administration of rimonabant in normal mice has helped in reducing their food intake. Acomplia (Rimonabant) is a class apart from other available diet pills as it works by selectively targeting and blocking the CB1 receptors. This procedure helps in normalizing the over-activation of the EC system and makes hunger or cigarette pangs more manageable for its users. The blocking of CB1 receptors by Acomplia that helps in controlling food cravings gradually results in weight loss, improvement of cardiovascular/ metabolic risk factors in overweight/obese patients and appears to reduce tobacco dependence without post cessation weight gain in people who smoke. So, apart from its weight loss benefits, Acomplia can provide great relief to smokers by helping them overcome the life threatening habit.

While nicotine patches, gums, lozenges and sprays help wean smokers off cigarettes by slowly reducing their dependence on nicotine, researchers are tailoring drugs to mimic or block nicotine’s chemical reactions with the body.In Connecticut, researchers at Pfizer Inc (search). identified a brain receptor that nicotine binds to and designed a drug, varenicline, that latches to the same site. Varenicline is in Phase III testing, normally the last step before a company applies for approval from the Food and Drug Administration.Researchers hope that the drug will attach to nicotine receptors in the brain, preventing overpowering cravings from setting in when someone stops smoking. If varenicline’s claims hold up, the drug could generate more than $501 million a year in sales, said David Moskowitz, an analyst with Friedman, Billings, Ramsey & Co (search).”It’s an unmet medical need,” said Dr. Karen Reeves (search), executive director of clinical development for Pfizer. “The morbidity and mortality rate is so high, and doctors and smokers really have not had enough in their armamentarium to help smokers stop smoking.”The French pharmaceutical company Sanofi-Synthelabo said it will ask for FDA approval this year for the drug Rimonabant-Acomplia, which it would market under the name Acomplia as a way to help stop smoking and overeating.Acomplia targets circuitry in the brain that encourages smokers to keep lighting up. If the body’s chemical reward system is blocked, smoking might not be as pleasurable or as addictive.Researchers have high hopes for the drug, saying it might also treat alcohol and drug abuse.

That combination could translate into billions in yearly sales, Moskowitz said.Then there’s NicVax, a drug that Florida-based Nabi Pharmaceuticals (search) claims could be used as a nicotine vaccine. NicVax triggers the production of antibodies that bind to nicotine molecules, preventing them from reacting with receptors in the brain.NicVax, which was developed primarily with grants from the National Institute on Drug Abuse, has shown promise in early trials and could begin Phase III testing late this year, the company said.A similar drug, called Ta-Nic, is in early testing by the Xenova Group in England.Whether one will be found remains uncertain, he said. It’s more likely, doctors agree, that scientists will develop a number of successful drugs that will prove effective, but no single pill will “cure” smoking.Doctors with high hopes have been let down before. In 1997, the FDA approved bupropion, commonly sold under the name Zyban, as an anti-smoking drug.The drug, which was originally marketed as an antidepressant, has proven successful for some smokers but was never the industry blockbuster some expected.

Dr. Cheryl Oncken, associate professor of medicine at the University of Connecticut Health Center, said the new drugs being developed represent the next generation of medicine. Oncken will present a research study this weekend on varenicline, which in an earlier Pfizer study was shown to help nearly half of smokers quit within seven weeks — compared to about 33 percent with bupropion.

Investors are proceeding cautiously. Scott Henry, a Pfizer analyst at Oppenheimer & Co., said it’s too early to tell whether there is a smoking wonder drug in development. He said varenicline has shown promise, but like all drugs being tested, there are many unanswered questions.

“Is it truly a revolutionary new treatment, or is just another bell and whistle?” he said.

Instead, it’s best to avoid faddy diets and devise your own reduced-calorie slimming diet based on what you currently eat, including some of your favourite foods.

WLR will set an appropriate calorie intake for you, based on whether you want to lose weight at a rate of ½lb, 1lb, 1½lb or 2lb a week – and then it’s simply a case of sticking to this daily calorie intake.

The good thing about this is that it allows you to adapt your diet to your lifestyle – rather than trying to change your lifestyle to fit around mealtimes. This means you can still create incredible meals if you love cooking or can simply heat up a ready meal if you don’t like, or have time, to spend hours in the kitchen.

Better still, cutting your calorie intake for slimming purposes isn’t usually as hard as it sounds. Often it is as simple as reducing your portion sizes slightly and/or making simple calorie swaps every day. For example, swapping a daily Danish pastry for a wholemeal scone will save a staggering 275 calories, while having a small 150ml glass of wine instead of a large 230ml glass will save almost 70 calories. Slimming really is that easy.

Getting Started
Most of us decide to start our slimming programme on the 1st January, but in reality, this is probably the worst week of the year to try and change your eating habits. After the excesses of Christmas and New Year, suddenly switching to a slimming programme will be a major shock to the system and is guaranteed to leave you quickly craving all the foods you’ve eaten to excess in the past month – we’re talking chocolates, wine, Christmas cake, cream, mince pies, nuts and crisps!

Instead, it’s far better to return to your normal pre-Christmas eating habits for a week or so, before starting your slimming programme. This will give you time to re-adjust to your ‘normal’ diet as well as giving you an opportunity to keep a food diary based on what you usually eat. Simply record every single mouthful that passes your lips for a week. It might sound tedious, but it will make you realise just how much you’re eating and help to identify any areas where you can make little changes to shift those pounds.

You may also find it helpful to keep a note of how you felt before eating. Was it because you were hungry? Was it to satisfy boredom, tiredness, unhappiness or another emotion? Or did you simply eat out of habit?

Identifying those times when you eat when you’re not really hungry will give you the opportunity to find other ways to deal with these situations rather than reaching for food. For example, if your food diary helps you realise that you eat when you’re bored, you can work towards beating boredom without using food, such as having a bath, going for a walk or phoning a friend for a gossip. Similarly, if your food diary reveals that you often eat out of habit, for example, by going straight to the fridge when you get home from work, you can look at ways to break or change those habits, for example, by heading straight for the fruit bowl!

Keeping on track
The key to continuing to lose weight is to keep your slimming and exercise programme fresh. If you eat the same foods day in and day out and only ever do the same activities, boredom will quickly set in with the result that you’ll be tempted to give up. When it comes to food, this might mean investing in a recipe book to try some new dishes or experimenting with different foods. For example, you could make it your weekly mission to buy a fruit or vegetable you’ve never tried before, or cook vegetables in different ways, such as roasting carrots with a little spray oil rather than steaming them, or adding fresh coriander, chopped peppers and spring onions to your usual salad of lettuce, tomato and cucumber! There are lots of different ways to keep meals interesting – it’s simply a case of experimenting.

The same goes for exercise. It’s natural that you’ll get bored if you only ever do the same activities – and on top of this, you’re unlikely to get the most out of your workout. Your body needs to be continuously pushed in order to burn fat and tone muscle so it’s important that you keep pushing yourself. This might mean trying some different cardiovascular machines if you go to the gym, or increasing the intensity of your workout, such as walking for a longer distance in the same amount of time. Keep an eye out for new activities too, such as dance classes at your local community centre or a new aqua aerobics class at the swimming pool.

It’s also essential to keep yourself motivated. In the early stages of your plan, friends and family will probably keep telling you how well you’re doing and how great you look, but compliments may gradually start to slow down, especially as people get used to seeing a slimmer you. That’s why it’s essential for you to keep reminding yourself of your slimming successes to date – that might mean trying on an old item of clothing that’s now too big for you, comparing pictures of yourself when you were bigger with ones of yourself now or simply totting up how many pounds and inches you’ve lost in total. You may also find it helpful to give yourself non-food treats such as a new haircut,(buy Rimonabant) a nail varnish or a massage, every time you reach a new goal.

Reaching a plateau
It’s also important to avoid getting disheartened if you reach a plateau where your weight seems to stick for a couple of weeks at a time, despite all your best efforts. This is common, but the good news is it’s usually only a temporary problem. In the meantime, there are several things you can do to help get those pounds shifting again. Start by checking your portion sizes. After weeks of following a slimming programme, many of us feel confident enough to ditch the kitchen scales and start putting cereal into a bowl rather than weighing it, or pouring dressing onto salad straight from the bottle rather than measuring out 1tbsp. Simply going back to weighing (cheap acomplia online) out servings of foods like cereals, rice, pasta, meat, poultry and fish may be all that it takes to get those pounds shifting again.

You may also find it helpful to keep a notebook with you for a week detailing every single mouthful you eat each day. In the same way that portions can increase over time, you might find you’ve allowed more treats to creep into your programme which you’ve been forgetting to add to your food diary, such as having the odd cake in the office, treating yourself to a bar of chocolate once a week, nibbling on sweets while you’re driving or pouring yourself a larger drink than normal.

2. I’ll never eat chocolate again
Ban any food and you’ll make it even more tempting with the result that you’ll end up overindulging as you try to curb your craving. It’s far more realistic to simply reduce the amount you eat – that might mean cutting down from two bars a day to one a day, or having chocolate just once a week instead of several times.

3. I’m going to be a size 8
You don’t have to look like Kylie or Kate Moss to be slim. We all have different sizes and shapes and most women will struggle to fit into a size-8 outfit. Instead, focus on setting a realistic target weight for you – and enjoy whatever size that makes you!

4. I’m going to cook everyday
There’s no need to turn yourself into a Domestic Goddess simply because you want to lose weight. Accept the fact that there will be times when you don’t have the time or inclination to cook and instead make the most of quick and easy dishes such as low-fat ready meals, beans on toast, jacket potatoes with tuna and salad and veggie stir fries.

5. I’ll go to the gym every day
Chances are you won’t have the time or energy to take up residence at your local gym and soon stop going completely as a result. Instead, see the gym as just one of the many ways you can build exercise into your daily life.

6. I’ll do it on my own
Good support is a vital component of any successful Weight Loss (forget about your weight loss problem) plan so prepare to ask for help and encouragement, whether that’s from a friend, partner or Weight Loss (forget about your weight loss problem) Resources.
 

Rimonabant targets an area in the brain called the Endocannabinoid System. It blocks the receptors in this area, meaning that Cannabinoids (chemical compounds containing ‘hungry’ messages) cannot reach the system. This lowers the intake of food, resulting in weight loss.(buy rimonabant)

The Endocannabinoid system affects the regulation of energy use, the breaking down of sugars, lipids and of the regulation of body weight and metabolism.Rimonabant targets visceral fat, a layer of fat which forms around internal organs. Reducing this layer of fat has been found to stem the production of harmful substances (order cheap rimonabant,such as cholesterol), which prevent the body responding to insulin. This effectively means that Rimonabant can lower the risk of diabetes and cardiovascular heart disease.

Is it Effective?

Trials of Rimonabant over the last few years have shown it to be an effective weight loss aid for some people. It was found that, of those taking 20mg tablets of Rimonabant, a third lost over 10% of their initial body weight, while over 60% lost over 5%. Average waist measurements are reported to have reduced by between 6 and 9 cm (3-4 inches,buy cheap generic rimonabant zimulti).

Patients followed a low calorie diet while taking the drug, and achieved better results than a control group following a low calorie diet and taking a placebo.

Participants in these trials also showed improved glucose control, cholesterol and triglyceride measurements from blood fats. These results show improvements of beyond what is expected from normal weight loss. For this reason, Rimonabant is believed to have positive effects on these measures. High-Density lipoprotein cholesterol (buy low cost rimonabant,The good cholesterol) measures had also improved beyond expected levels.

Side Effects and Maintenance

Side effects of this drug are known to include diarrhoea, nausea and anxiety, this provoked a 15% drop out rate among participants in the trial.For most patients Rimonabant only remained effective for weight loss for up to about 34 weeks, though continuous use of the drug has been shown to maintain the weight loss (purchase rimonabant cheap).After ending their use of Rimonabant, most patients regained most of the weight they had lost.

So is this now the best way to lose weight?

Not necessarily. As with all diet drugs, there are potential side affects. The group taking the drug were slightly more likely to experience symptoms such as nausea, anxiousness, influenza and depressed mood disorder.Also, most of the patients who were switched to the placebo after one year were seen to regain most of their lost weight by the end of year two, so unless taken every day over a very long period of time, it does not appear to be a permanent solution.(order rimonabant,best way to lose weight)

While the tests have shown positive results, you can comfortably and healthily lose 2lbs per week, more than the majority of the patients involved in the trial, simply by increasing activity and making sensible changes to your diet.So like other medical methods, (order cheap rimonabant,best way to lose weight,and forget about your weight problems) this should be treated as a last resort rather than the first option looked at when starting the fight to lose weight.

They worked on the idea that if substances from cannabis called cannabinoids stimulated appetite, blocking the cannabinoid receptors in the brain might reduce appetite.Furthermore, blocking these receptors might also help people to give up smoking as these receptors not only appear to be involved in controlling food intake, but also have a role to play in tobacco dependence.(buy cheap rimonabant zimulti)

Earlier trials with the drug, which works by blocking cannabinoid receptors in the brain, have already shown promising results. But now a new study published in medical journal The Lancet, confirms the drug can help with weight loss and reduce the risk factors associated with heart disease.(new weight loss pill rimonabant)

In the study, more than 1,500 obese people were given a calorie-controlled diet, together with either 5mg or 20mg of rimonabant each day or a dummy drug. After one year, two thirds of the participants taking the largest dose had lost at least 5 percent of their weight. Better still, of these, 39 percent lost more than 10 percent. Meanwhile, patients on the 20mg dose lost on average, 4cm from their waist and risk factors for heart disease including raised cholesterol, insulin resistance and the presence of metabolic syndrome improved.(new weight loss pills acomplia)

Professor Luc Van Gaal who led the study says, “In this study, treatment with rimonabant over one year led to sustained, clinically meaningful weight loss, reduction in waist circumference and associated improvements in several cardiovascular risk factors.”

Weight Loss Resources says…

It’s great that research continues to be carried out in an effort to help find a drug that can aid weight loss. However, it’s unlikely we’ll ever be in a situation where diet and exercise become redundant in the fight against obesity. Finding a miracle pill that enables us to lose weight while constantly overindulging on a poor diet and doing no exercise is still a long way off. Even in this study, the participants had to follow a calorie-controlled diet!(purchase rimonabant)

With regard to this drug, more trials still need to be carried out, although the manufacturers are hoping the drug, which will be marketed under the name Acomplia, will be available next year. We’ll keep you updated on any progress but in the meantime, it’s not worth getting too excited and giving up your diet!(buy Rimonabant)

A closer look at the data shows that while the weight loss achieved with rimonabant is statistically significant and certainly improves health, in real terms, losing 10 percent of your weight is unlikely to get you into those size-10 trousers you’ve always dreamed of!(order Rimonabant)

The drug is only suitable for people who have a body mass index of over 30 or over 27 if there are other health problems. This means someone who weighs 14st, may lose up to 20lb in a year by taking this drug. That’s good news, but let’s face it, most of us can achieve this – and a whole lot more – by dieting and exercising alone. Bottom line, even if this drug does get approved, it might help you lose some weight and improve your overall heart health – but it won’t make you skinny!

Who is Acomplia For?

Clinical trials have found that Rimonabant can help overweight and obese people to lose weight. It was also found that the drug could reduce the risk of cardiovascular heart disease and diabetes, and be of help to people who are trying to stop smoking.

As of June 28th, Acomplia is available only to private patients with prescription, as the drug is currently awaiting approval of the National Institute for Health and Clinical Excellence (NICE) which is expected to take two years. If Acomplia is approved it is likely that obese (BMI over 30) patients, and overweight (BMI over 25) patients considered to be at high risk of type 2 diabetes or cardiovascular disease, could be offered the tablets.

However it has been noted that this weight loss treatment could cost the NHS billions, with each Acomplia tablet costing $1.97 - $55.20 per patient per month.